Literature DB >> 33364199

The Lipid Metabolic Landscape of Cancers and New Therapeutic Perspectives.

Wenjun Wang1, Ling Bai1, Wei Li1, Jiuwei Cui1.   

Abstract

Lipid metabolism reprograming, as a hallmark of malignancy, has received renewed interest in recent years in such areas as energy sources, cell membrane components, and signaling molecules involved in the rapid tumor growth and the adaptation to the tumor microenvironment. Lipid metabolism deregulation in cancer involves multiple aspects, including an increased lipid uptake, endogenous de novo fatty acid synthesis, fatty acid oxidation, and cholesterol accumulation, thereby promoting tumor growth and progression. Recent advances in the understanding of specific metabolic alterations in cancer reveal novel pathogenesis mechanisms and a growing number of drugs targeting lipid metabolism have been applied in anti-tumor therapy. Thus, this review discusses the lipid metabolic landscape of cancers and the interplay with oncogenic signaling, and summarizes potential therapeutic targets to improve the therapeutic efficiency in cancer patients, in order to provide more reference and thinking for the treatment of lipid metabolism of cancer patients.
Copyright © 2020 Wang, Bai, Li and Cui.

Entities:  

Keywords:  cancer; cancer metabolism; cholesterol; fatty acid catabolism; fatty acid synthesis; lipid uptake; tumor microenvironment

Year:  2020        PMID: 33364199      PMCID: PMC7753360          DOI: 10.3389/fonc.2020.605154

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  20 in total

1.  Nutrition Research Funding Trends and Focus Areas at the US National Cancer Institute.

Authors:  Elaine B Trujillo; Cameron Hays; Karen Regan; Sharon Ross; Harold Seifried
Journal:  JNCI Cancer Spectr       Date:  2022-09-01

Review 2.  Hypercholesterolemia in Cancer and in Anorexia Nervosa: A Hypothesis for a Crosstalk.

Authors:  Giulia Gizzi; Samuela Cataldi; Claudia Mazzeschi; Elisa Delvecchio; Maria Rachele Ceccarini; Michela Codini; Elisabetta Albi
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

3.  Plasma lipids signify the progression of precancerous gastric lesions to gastric cancer: a prospective targeted lipidomics study.

Authors:  Zong-Chao Liu; Wen-Hui Wu; Sha Huang; Zhong-Wu Li; Xue Li; Guang-Hou Shui; Sin Man Lam; Bo-Wen Li; Zhe-Xuan Li; Yang Zhang; Tong Zhou; Wei-Cheng You; Kai-Feng Pan; Wen-Qing Li
Journal:  Theranostics       Date:  2022-06-06       Impact factor: 11.600

4.  Identification of solute-carrier family 27A molecules (SCL27As) as a potential biomarker of ovarian cancer based on bioinformatics and experiments.

Authors:  Hao Chen; Tao Han; Yi Zhao; Liang Feng
Journal:  Ann Transl Med       Date:  2021-08

5.  Small Molecule Targeting of Oxysterol-Binding Protein (OSBP)-Related Protein 4 and OSBP Inhibits Ovarian Cancer Cell Proliferation in Monolayer and Spheroid Cell Models.

Authors:  Ryan C Bensen; Gokhan Gunay; Matthew C Finneran; Isha Jhingan; Handan Acar; Anthony W G Burgett
Journal:  ACS Pharmacol Transl Sci       Date:  2021-02-04

Review 6.  Metabolic Classification and Intervention Opportunities for Tumor Energy Dysfunction.

Authors:  Ezequiel Monferrer; Isaac Vieco-Martí; Amparo López-Carrasco; Fernando Fariñas; Sergio Abanades; Luis de la Cruz-Merino; Rosa Noguera; Tomás Álvaro Naranjo
Journal:  Metabolites       Date:  2021-04-23

7.  Synthesis and biological evaluation of 4-phenoxy-phenyl isoxazoles as novel acetyl-CoA carboxylase inhibitors.

Authors:  Xin Wu; Yongbo Yu; Tonghui Huang
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

8.  Metabolic syndrome related gene signature predicts the prognosis of patients with pancreatic ductal carcinoma. A novel link between metabolic dysregulation and pancreatic ductal carcinoma.

Authors:  Weiyang Cai; Wenming Bao; Shengwei Chen; Yan Yang; Yanyan Li
Journal:  Cancer Cell Int       Date:  2021-12-20       Impact factor: 5.722

Review 9.  Lipid Metabolism Regulation Based on Nanotechnology for Enhancement of Tumor Immunity.

Authors:  Bin Tu; Yanrong Gao; Feifei Sun; Mingjie Shi; Yongzhuo Huang
Journal:  Front Pharmacol       Date:  2022-03-22       Impact factor: 5.810

10.  Anthracyclins Increase PUFAs: Potential Implications in ER Stress and Cell Death.

Authors:  David Balgoma; Fredrik Kullenberg; Carlemi Calitz; Maria Kopsida; Femke Heindryckx; Hans Lennernäs; Mikael Hedeland
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.